Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex

Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex

Background: Rifamycins are the cornerstone of anti-tuberculosis therapy while they are potent inducers of drug metabolizing enzymes. For the first time, we evaluated the effect of rifampicin (RIF) and rifabutin (RBT) on the pharmacokinetics (PK) of dolutegravir (DTG) in patients with HIV and tubercu...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Xiaoqin Le, Xiaoye Guo, Jianjun Sun, Li Liu, Yinzhong Shen, Jiangrong Wang, Tangkai Qi, Zhenyan Wang, Yang Tang, Wei Song, Lin Yin, Lijun Zhang, Renfang Zhang, Jun Chen
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Elsevier 2022-03-01
Cyfres:International Journal of Infectious Diseases
Pynciau:
HIV
tuberculosis
pharmacokinetics
dolutegravir
rifampicin
rifabutin
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S1201971222000029

Rhyngrwyd

http://www.sciencedirect.com/science/article/pii/S1201971222000029

Eitemau Tebyg